[{"notes_id":"1_958","category":"5","subcategory":"1","title":"Post-exposure prophylaxis","body":"Hepatitis A<br \/><ul><li>Human Normal Immunoglobulin (HNIG) or hepatitis A vaccine may be used depending on the clinical situation<ul><li>HNIG is typically reserved for those who cannot receive the vaccine or where rapid protection is required (e.g. immunosuppressed individuals)<\/li><li>In most cases, <b>hepatitis A vaccine is preferred<\/b> for post-exposure prophylaxis<\/li><\/ul><\/li><\/ul><br \/>Hepatitis B<br \/><ul><li>HBsAg positive source<ul><li>If the person exposed is a <b>known responder<\/b> (anti-HBs \u226510 mIU\/mL following full vaccination), a <span class=\"concept\" data-cid=\"12393\">booster dose should be given<\/span><\/li><li>If they are a <b>non-responder<\/b> (anti-HBs <10 mIU\/mL 1\u20132 months after completing the full course), they should receive <span class=\"concept\" data-cid=\"11851\">hepatitis B immunoglobulin (HBIG) and a booster vaccine<\/span><\/li><\/ul><\/li><li>Unknown source<ul><li>For known responders, a booster dose may be considered depending on the risk assessment<\/li><li>For non-responders, <b>HBIG and a booster vaccine<\/b> should be given<\/li><li>Individuals undergoing a primary course of vaccination should complete an accelerated schedule and may be offered HBIG if the risk of exposure is considered high<\/li><\/ul><\/li><\/ul><br \/>Hepatitis C<br \/><ul><li>There is <span class=\"concept\" data-cid=\"12391\"><b>no effective post-exposure prophylaxis<\/b> for hepatitis C<\/span><\/li><li>Initial testing should include baseline HCV serology and HCV RNA (PCR)<\/li><li>Repeat HCV RNA at 6 and 12 weeks post-exposure, and HCV antibody at 3 and 6 months<\/li><li>If seroconversion occurs, early referral to hepatology for consideration of <b>direct-acting antiviral therapy<\/b> is advised<\/li><\/ul><br \/>HIV<br \/><ul><li>The risk of HIV transmission depends on the nature of the exposure (e.g. needlestick, type of sexual contact, human bite) and the <span class=\"concept\" data-cid=\"10630\"><b>viral load<\/b><\/span> of the source individual<\/li><li>Low-risk incidents such as <span class=\"concept\" data-cid=\"8596\"><b>human bites<\/b><\/span> generally do not require post-exposure prophylaxis (PEP), unless blood is present or other risk factors apply<\/li><li>First-line PEP regimen is oral antiretroviral therapy: <span class=\"concept\" data-cid=\"12392\"><b>tenofovir disoproxil\/emtricitabine (Truvada\u00ae) + raltegravir<\/b><\/span><ul><li>PEP should be started <b>as soon as possible<\/b> (ideally within 1\u20132 hours, and no later than 72 hours post-exposure)<\/li><li>Treatment course lasts <span class=\"concept\" data-cid=\"947\"><b>4 weeks<\/b><\/span><\/li><\/ul><\/li><li>HIV serological testing is required at <b>12 weeks after completing PEP<\/b><\/li><li>PEP reduces the risk of HIV transmission by approximately <b>80%<\/b><\/li><\/ul><br \/>Varicella zoster<br \/><ul><li>Varicella zoster immunoglobulin (VZIG) should be given to <b>IgG-negative pregnant women or immunosuppressed individuals<\/b> after significant exposure<ul><li>If VZIG is unavailable or >10 days post-exposure, <b>oral aciclovir<\/b> may be considered (based on risk assessment)<\/li><\/ul><\/li><\/ul><br \/><h5 class='notes-heading'>Estimates of transmission risk for single needlestick injury<\/h5><br \/><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th>Virus<\/th><th>Chance of transmission<\/th><\/tr><\/thead><tbody><tr><td>Hepatitis B<\/td><td>20\u201330% (if source is HBeAg positive)<\/td><\/tr><tr><td>Hepatitis C<\/td><td>0.5\u20132%<\/td><\/tr><tr><td>HIV<\/td><td>0.3%<\/td><\/tr><\/tbody><\/table><\/div>","notes_hash":"f1a07335df457aa60f542f9c0c5c5c11","knowledge_graph_node_id_link":0,"links":"<table style='width:100%'><tr><td>BHIVA<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_511\" data-linkid=\"511\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_511\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">7<\/span><button type=\"button\" style=\"\" id=\"link_dislike_511\" data-linkid=\"511\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_511\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">20<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/bhiva.org\/clinical-guideline\/pep-guidelines\/\">Post-exposure prophylaxis following sexual exposure<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>Green Book<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1226\" data-linkid=\"1226\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1226\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">9<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1226\" data-linkid=\"1226\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1226\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">11<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.gov.uk\/government\/publications\/hepatitis-b-the-green-book-chapter-18\">Hepatitis B guidelines<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>Department of health<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_165\" data-linkid=\"165\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_165\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">3<\/span><button type=\"button\" style=\"\" id=\"link_dislike_165\" data-linkid=\"165\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_165\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">4<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/203139\/HIV_post-exposure_prophylaxis.pdf\">HIV post-exposure prophylaxis<\/a><\/td><\/tr><\/table>","media":"","concepts_for_notes":{"947":{"concept_text":"Post-exposure prophylaxis for HIV: oral antiretroviral therapy for 4 weeks","concept_percentile":"88"}},"category_name":"Infectious disease \/ Haematology \/ Immunology","subcategory_name":"Infectious disease","comment_count":9},"",[]]